Tirzepatide Starting Dose

Switching from semaglutide does not skip the step

There is no validated milligram-for-milligram conversion between semaglutide and tirzepatide. Patients moving across usually restart at 2.5 mg roughly a week after their final semaglutide injection, then titrate normally. Some clinicians will begin at 5 mg for a patient already well tolerant of a high semaglutide dose, but that is a judgment call made by the prescriber.

What to expect in the first four weeks

Appetite suppression is usually noticeable within days. Weight change in the first month is modest and highly variable, and a large part of any rapid early drop is fluid and reduced food volume rather than fat.

What the starter month should cost you

Compare the twelve-month figure rather than the first invoice. A program with a low starter price and steep dose-scaling can finish the year more expensive than one that charges a flat rate from day one.

Where this fits in the whole course

Tirzepatide is a fifty-two-week decision at minimum, not a four-week one. The titration rules on this page govern the first three to six months; the maintenance dose you land on governs the rest of the year and, on current evidence, the years after it. Both halves have a cost consequence.

What this dose stage costs

Compounded tirzepatide across the 21 compounded programs we track runs $133 to $399 per month at the entry dose, and a first year on the standard escalation starts around $2,388 at Oak Longevity. 18 of those programs hold one price at every strength; 3 reprice as you escalate. Brand routes through the manufacturer's self-pay channel sit well above the compounded band and well below pharmacy retail.

What to document as you go

Keep three things written down from the first injection: the date and strength of every dose, the injection site, and any adverse effect with the day it started relative to a dose change. That record is what lets a prescriber distinguish a tolerance problem from an unrelated illness, and it takes ten seconds a week.

Tirzepatide Starting Dose: the four-week rule in practice

The labelled minimum interval between tirzepatide increases is four weeks, and the interval exists for tolerability rather than efficacy. Gastrointestinal adverse events cluster in the days after each step and settle as the gut adapts; escalating faster does not accelerate weight loss in any published trial but reliably increases nausea, which is the single most common reason patients abandon treatment in the first quarter.

Repeating a step is normal practice, not a setback. Roughly a third of patients hold at least one strength for an extra cycle, which pushes the maintenance dose four to eight weeks later than the theoretical minimum and changes nothing about the eventual outcome. Time on therapy predicts results; speed of escalation does not.

Tirzepatide Starting Dose: the cost consequence

Every dose decision is also a price decision at the 3 tracked programs that reprice with strength. Compounded tirzepatide starts at $133 per month at entry, and the cheapest tracked route holds a 10 mg maintenance dose at $199 — about $2,388 for a first year. Price the strength you expect to maintain on before you enrol anywhere, because the advertised figure describes roughly four weeks of a twelve-month course.

Tirzepatide Starting Dose: when to involve your prescriber immediately

Severe abdominal pain radiating to the back, inability to keep fluids down for a day, a new neck lump or hoarseness, sudden vision change, fainting, or signs of a systemic allergic reaction all warrant prompt contact rather than waiting for a scheduled check-in. Everything else — the nausea, the constipation, the fatigue of the first fortnight — is ordinary adaptation and is covered in the side-effect reference.

Tirzepatide Starting Dose: what to write down

Three records make every conversation with a prescriber shorter and every insurance appeal stronger: the date and strength of every dose, any adverse effect with the day it began relative to a dose change, and your weight measured under identical conditions weekly rather than daily. None of it takes more than a minute a week, and all of it is the evidence a clinician needs to distinguish a tolerance problem from an unrelated illness.

Tirzepatide Starting Dose: where the numbers on this page come from

Clinical statements follow the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial reports, cited with their registration identifiers so you can read the primary source rather than our summary of it. Price figures come from our tracked dataset, which is downloadable and carries a verification date on every record. Where we could not verify something we say so rather than estimating; where our sources disagree we show both figures rather than choosing one.

Tirzepatide Starting Dose: what changes if you are switching from semaglutide

Nothing about the ladder changes. There is no validated milligram conversion between semaglutide and tirzepatide in either direction, so a switch means starting tirzepatide at 2.5 mg regardless of the semaglutide dose you were taking, typically about a week after the final semaglutide injection. Some clinicians will begin a well-tolerated patient at 5 mg; that is a judgement call for a prescriber with your record, not a rule you can apply yourself.

The compensation is that a switch is usually easier than a first-ever start. Some tolerance to GLP-1 receptor effects persists, so the initiation nausea tends to be milder. Judge the switch at month four rather than month one, because month one is a starter dose either way.

Tirzepatide Starting Dose: the practical setup nobody mentions

Before the first injection, five things are worth having in place: a fixed weekly injection day with a phone reminder; a sharps container, because household bins are not appropriate for needles; a refrigerator thermometer, since door shelves swing through wide temperature ranges and the back wall of many domestic fridges drops below freezing; a protein target you can actually hit on a suppressed appetite; and a written note of what your program charges at 10 mg so month four is not a surprise.

Tirzepatide Starting Dose: what the dose does not control

Dose governs appetite signalling. It does not govern what you eat when you are not hungry, whether you keep lean mass, how you sleep, or whether you can afford to continue — and those four determine most of the difference between people on identical prescriptions. Resistance training two to three times a week through the course, rather than after it, is the single highest-leverage thing outside the syringe.

Tirzepatide Starting Dose: the questions worth taking to a prescriber

Consultations are short and the useful ones are prepared for. Five questions cover most of what this page raises: what maintenance dose do you expect me to reach, and by when; what would make you hold or reduce rather than escalate; which of my existing medications need reviewing alongside this one; what monitoring do you want and at what interval; and what would make you stop treatment altogether. Written answers to those five are worth more than any amount of reading.

Tirzepatide Starting Dose: how this page is maintained

Clinical statements follow the tirzepatide prescribing information and the published trial program, cited with registration identifiers so the primary source is one click away. Price figures come from a tracked dataset that carries a verification date on every record and is published in full. Where evidence is limited we say so rather than filling the gap with confident language, and where our sources disagree we show both figures. Errors go in the corrections log with the date they were fixed.

Tirzepatide Starting Dose: what patients get wrong most often

Four mistakes recur, and all four are expensive. Judging the drug on the first month, when the starter dose is not a treatment dose and a flat scale predicts nothing. Comparing programs on the advertised price, which describes four weeks of a twelve-month course. Treating a plateau as failure rather than as the expected shape of the trial curves. And stopping for cost without pricing the market first, when the spread between the cheapest and dearest route to the identical molecule runs from $133 to $399 a month at entry.

The fifth, less common but more serious, is buying outside the licensed channel because a price looked unbeatable. Research-labelled peptide sold without a prescription is a different market with no clinical oversight and no accountability if something goes wrong, and the disclaimer that it is not for human consumption exists so the seller can say you were told.

Tirzepatide Starting Dose: the three-year view

Current evidence treats obesity pharmacotherapy as ongoing while it remains effective, tolerated and appropriate, and the withdrawal data show substantial regain after stopping. That makes three years a more honest planning horizon than twelve months. At the cheapest tracked route, holding a 10 mg maintenance dose for three years costs roughly $7,164; at the dearest compounded route it is several times that for the same molecule. Deciding on a first-month price is deciding on the least representative number available.

Tirzepatide Starting Dose: what would change this page

New trial evidence, a change in the labelling, a shift in the compounding framework, or a correction from a reader. Clinical statements here follow the prescribing information and the published trial program; price figures carry a verification date and sit in a downloadable dataset. Where the evidence is genuinely limited — long-term data beyond the trial horizon, bioavailability of compounded oral preparations, the human relevance of the rodent thyroid finding — this site says so rather than filling the gap with confident language, and updates rather than defends when better evidence arrives.

Tirzepatide Starting Dose: the shortest useful summary

Tirzepatide is a once-weekly injection titrated from 2.5 mg to a 15 mg ceiling in 2.5 mg steps at intervals of at least four weeks, producing roughly 15 to 21% mean weight reduction across the studied maintenance arms at 72 weeks and about 20% against semaglutide's 14% in the only head-to-head trial. It works while it is taken; the withdrawal evidence shows substantial regain after stopping. Compounded preparations cost from $133 a month and are not FDA-approved; brand product is approved and costs considerably more.

Those five facts decide most questions people arrive with. Everything else on this page is detail underneath them — which is worth reading before you spend $2,388 on a first year, but not worth confusing with the outline.

Tirzepatide Starting Dose: where to go next

If you have not chosen a program, price your expected maintenance dose with the projector rather than reading advertisements. If you have, check what it charges at 10 mg against the price-by-dose table. If you are struggling with side effects, the side-effect reference covers each one with reported frequencies and the red flags that need a clinician. And if a program has refused to name its pharmacy, the verification walkthrough explains why that single answer outranks any price difference.